A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Conditions: Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma Interventions: Biological: Pembrolizumab co-formulated with hyaluronidase; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06099782

Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials